Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Autoimmune Disorders01:29

Autoimmune Disorders

1.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.2K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.5K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

2.3K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.3K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

295
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
295

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Frontiers in immunology·2026
Same author

Global overview of multiple sclerosis care units: an international cross-sectional survey.

Frontiers in neurology·2026
Same author

A nationwide temporal analysis of socioeconomic outcomes in Denmark's multiple sclerosis population.

Multiple sclerosis and related disorders·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Nationwide prevalence and incidence of MOG antibody-associated disease (MOGAD) in Denmark.

Multiple sclerosis and related disorders·2026
Same author

Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program.

Neurology. Clinical practice·2026

Related Experiment Video

Updated: Dec 7, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K

Comorbidity in Multiple Sclerosis.

Melinda Magyari1,2, Per Soelberg Sorensen1

  • 1Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital, Rigshospitalet, Denmark.

Frontiers in Neurology
|September 25, 2020
PubMed
Summary
This summary is machine-generated.

Comorbidities, or coexisting diseases, are common in multiple sclerosis (MS) patients. These conditions significantly impact MS presentation, treatment, and patient outcomes, highlighting the need for integrated care.

Keywords:
coexisting diseasescomorbiditiescomorbidity [MeSH]multiple sclerosisregistry

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.5K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.0K

Related Experiment Videos

Last Updated: Dec 7, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.8K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.5K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.0K

Area of Science:

  • Neurology
  • Immunology
  • Public Health

Background:

  • Multiple sclerosis (MS) patient care is increasingly focused on comorbidities, defined as coexisting diseases not caused by the primary condition.
  • Understanding the prevalence and impact of comorbidities in MS is crucial for comprehensive patient management.

Purpose of the Study:

  • To review current evidence on the range of comorbidities in patients with multiple sclerosis (MS) across different countries.
  • To explore the influence of comorbidities on the clinical features, diagnostic delay, and therapeutic challenges in MS.

Main Methods:

  • Systematic review of existing literature on comorbidities in multiple sclerosis (MS).
  • Analysis of reported data on comorbidity prevalence, clinical impact, and management challenges.

Main Results:

  • Common comorbidities in MS include depression, anxiety, cardiovascular diseases, diabetes, thyroid disease, and inflammatory bowel disease.
  • Comorbidities can alter MS clinical presentation, increase disability progression (e.g., diabetes, hypertension, COPD), and affect quality of life.
  • No evidence suggests a higher cancer risk in MS patients, despite previous perceptions.

Conclusions:

  • Comorbidities are prevalent in MS patients from diagnosis, contributing to heterogeneity in disease progression and healthcare utilization.
  • Managing comorbidities alongside MS, especially with polypharmacy and advanced therapies, presents significant clinical challenges.
  • Integrated care approaches are essential to address the complex needs of MS patients with coexisting conditions.